

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the preliminary views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission. The information transmitted is intended only for the Member State or entity to which it is addressed for discussions and may contain confidential and/or privileged material.

EN

ANNEX

The Annex to Implementing Regulation (EU) 2017/2470 is amended as follows:

(1) in Table 1 (Authorised novel foods), the following entry is inserted in alphabetical order:

Authorised novel food	Conditions under which the novel food may be used		Additional specific labelling requirements	Other requirements	Data protection
Nonapeptide-pentapeptide mixture	<i>Specified food category</i>	<i>Maximum levels</i>	The designation of the novel food on the labelling of food supplements containing it shall be ‘nonapeptide-pentapeptide mixture (1)’. The labelling of food supplements containing ‘nonapeptide-pentapeptide mixture’ shall bear a statement that they should not be consumed by persons under 18 years of age, and pregnant and lactating women.		Authorised on [...] <i>[OP, please insert the date dd.mm.yyyy - 20th day following its publication]</i> . This inclusion is based on proprietary scientific evidence and scientific data protected in accordance with Article 26 of Regulation (EU) 2015/2283.
	Food supplements as defined in Directive 2002/46/EC, for the general adult population, excluding pregnant and lactating women.	14 mg/day			

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the preliminary views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission. The information transmitted is intended only for the Member State or entity to which it is addressed for discussions and may contain confidential and/or privileged material.

			Applicant: “ Caregen Co., Ltd ”, 16-27 LS-ro 91beon-gil, Dongan-gu, Angang-si Gyeonggi-do, 14119, South Korea . During the period of data protection, the novel food nonapeptide-pentapeptide mixture is authorised for placing on the market within the Union only by “Caregen Co., Ltd” unless a subsequent applicant obtains authorisation for the novel food without reference to the proprietary scientific evidence or scientific data protected in accordance with Article 26 of
--	--	--	--

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the preliminary views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission. The information transmitted is intended only for the Member State or entity to which it is addressed for discussions and may contain confidential and/or privileged material.

				Regulation (EU) 2015/2283 or with the agreement of “Caregen Co., Ltd”. End date of the data protection: [...] [OP please insert the date dd.mm.yyyy – after 5 years].
--	--	--	--	--

,

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the preliminary views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission. The information transmitted is intended only for the Member State or entity to which it is addressed for discussions and may contain confidential and/or privileged material.

(2) in Table 2 (Specifications), the following entry is inserted in alphabetical order:

Authorised novel food	Specification
Nonapeptide-pentapeptide mixture	Description: The novel food is a powdered mixture of two peptides (Nonapeptide: lysine-glycine-serine-alanine-threonine-glycine-tryptophan-methionine-alanine and Pentapeptide: leucine-lysine-threonine-arginine-asparagine) in an approximately 1:1 ratio. The two peptides are independently produced by solid-phase chemical synthesis and then mixed with resistant maltodextrin in a ratio of 1:99. Characteristics/Composition Sum of Nonapeptide and Pentapeptide: $\geq 95\%$ Nonapeptide assay¹ (%): 45–55% Pentapeptide assay¹ (%): 45–55% Moisture: $\leq 5\%$ Residual solvents N,N-Dimethylformamide: ≤ 0.004 mg/kg tert-Butyl methyl ether: ≤ 100 mg/kg Methylene chloride (Dichloromethane): ≤ 0.002 mg/kg Acetonitrile: ≤ 200 mg/kg Trifluoroacetic acid (TFA): ≤ 250 mg/kg Methyl alcohol: ≤ 10 mg/kg

¹ Assay refers to the quantitative determination of peptide content in the test sample calculated against defined concentrations of the peptide reference standards for the generation of a calibration curve to calculate the peptide content of samples of the same peptide, i.e., the actual amount of peptide present in the sample.

This draft has not been adopted or endorsed by the European Commission. Any views expressed are the preliminary views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission. The information transmitted is intended only for the Member State or entity to which it is addressed for discussions and may contain confidential and/or privileged material.

	Processing Aids 2-(1H-benzotriazol-1-yl)-1,1,3,3- tetramethyluronium hexafluorophosphate (HBTU): <1.2 mg/kg Hydroxybenzotriazole (HOBt): <0.7 mg/kg Fluorenylmethyloxycarbonyl (fmoc): < 2 mg/kg Thionyl chloride: < 0.6 mg Piperidine: < 1.9 mg/kg N,N-Diisopropylethylamine (DIEA) : < 4.8 mg/kg 1,2-Ethanedithiol (EDT): < 3.6 mg/kg Thioanisole: < 4.2 mg/kg Heavy Metals Arsenic: ≤0.02 mg/kg Microbiological criteria Total plate count: <100 CFU²/g Total Coliforms: Not detected in 25g Salmonella spp.: Not detected in 25g Yeast and mould: <100 CFU/g
--	--

² CFU = colony forming units